Human Insulin Drugs Market in Brazil 2024-2028

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,500	142 Pages	TechNavio	December, 2023	INF18413862

Best Price Guarantee
Price	from $2,500
Length	142 Pages
Publisher	TechNavio
Published Date	December, 2023
SKU	INF18413862

Human Insulin Drugs Market In Brazil 2024-2028

The human insulin drugs market in Brazil is forecasted to grow by USD 181.76 mn during 2023-2028, accelerating at a CAGR of 6.5% during the forecast period. The report on the human insulin drugs market in Brazil provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of diabetes in Brazil, demographic transition in Brazil, and increasing awareness of insulin therapy.

Technavio's human insulin drugs market in Brazil is segmented as below:

By Product

Basal insulin analog
NPH (Neutral Protamine Hagedorn)

By Application

Type I diabetes
Type II diabetes

By Distribution Channel

Retail
Hospitals

This study identifies the advent of biosimilars for treatment of diabetes as one of the prime reasons driving the human insulin drugs market in Brazil growth during the next few years. Also, increasing initiatives by vendors and technological advancements in human insulin drugs will lead to sizable demand in the market.

The report on the human insulin drugs market in Brazil covers the following areas:

Human insulin drugs market in Brazil sizing
Human insulin drugs market in Brazil forecast
Human insulin drugs market in Brazil industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading human insulin drugs market in Brazil vendors that include Becton Dickinson and Co., Biocon Ltd., Biomm, Eli Lilly and Co., Empreendimentos Pague Menos SA, Gulf Pharmaceutical Industries, MannKind Corp., Medtronic Plc, Merck and Co. Inc., Novartis AG, Novo Nordisk AS, Sanofi SA, and Wockhardt Ltd.. Also, the human insulin drugs market in Brazil analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

1 Executive Summary: 1.1 Market overview; Exhibit 01: Executive Summary - Chart on Market Overview; Exhibit 02: Executive Summary - Data Table on Market Overview; Exhibit 03: Executive Summary - Chart on Country Market Characteristics; Exhibit 04: Executive Summary - Chart on Market Segmentation by Product; Exhibit 05: Executive Summary - Chart on Market Segmentation by Application; Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel; Exhibit 07: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape: 2.1 Market ecosystem; Exhibit 08: Parent market; Exhibit 09: Market Characteristics
3 Market Sizing: 3.1 Market definition; Exhibit 10: Offerings of vendors included in the market definition; 3.2 Market segment analysis; Exhibit 11: Market segments; 3.3 Market size 2023; 3.4 Market outlook: Forecast for 2023-2028; Exhibit 12: Chart on Brazil - Market size and forecast 2023-2028 ($ million); Exhibit 13: Data Table on Brazil - Market size and forecast 2023-2028 ($ million); Exhibit 14: Chart on Brazil: Year-over-year growth 2023-2028 (%); Exhibit 15: Data Table on Brazil: Year-over-year growth 2023-2028 (%)
4 Historic Market Size: 4.1 Human insulin drugs market in Brazil 2018 - 2022; Exhibit 16: Historic Market Size - Data Table on human insulin drugs market in Brazil 2018 - 2022 ($ million); 4.2 Product Segment Analysis 2018 - 2022; Exhibit 17: Historic Market Size - Product Segment 2018 - 2022 ($ million); 4.3 Application Segment Analysis 2018 - 2022; Exhibit 18: Historic Market Size - Application Segment 2018 - 2022 ($ million); 4.4 Distribution Channel Segment Analysis 2018 - 2022; Exhibit 19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
5 Five Forces Analysis: 5.1 Five forces summary; Exhibit 20: Five forces analysis - Comparison between 2023 and 2028; 5.2 Bargaining power of buyers; Exhibit 21: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028; 5.3 Bargaining power of suppliers; Exhibit 22: Bargaining power of suppliers - Impact of key factors in 2023 and 2028; 5.4 Threat of new entrants; Exhibit 23: Threat of new entrants - Impact of key factors in 2023 and 2028; 5.5 Threat of substitutes; Exhibit 24: Threat of substitutes - Impact of key factors in 2023 and 2028; 5.6 Threat of rivalry; Exhibit 25: Threat of rivalry - Impact of key factors in 2023 and 2028; 5.7 Market condition; Exhibit 26: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Product: 6.1 Market segments; Exhibit 27: Chart on Product - Market share 2023-2028 (%); Exhibit 28: Data Table on Product - Market share 2023-2028 (%); 6.2 Comparison by Product; Exhibit 29: Chart on Comparison by Product; Exhibit 30: Data Table on Comparison by Product; 6.3 Basal insulin analog - Market size and forecast 2023-2028; Exhibit 31: Chart on Basal insulin analog - Market size and forecast 2023-2028 ($ million); Exhibit 32: Data Table on Basal insulin analog - Market size and forecast 2023-2028 ($ million); Exhibit 33: Chart on Basal insulin analog - Year-over-year growth 2023-2028 (%); Exhibit 34: Data Table on Basal insulin analog - Year-over-year growth 2023-2028 (%); 6.4 NPH (Neutral Protamine Hagedorn) - Market size and forecast 2023-2028; Exhibit 35: Chart on NPH (Neutral Protamine Hagedorn) - Market size and forecast 2023-2028 ($ million); Exhibit 36: Data Table on NPH (Neutral Protamine Hagedorn) - Market size and forecast 2023-2028 ($ million); Exhibit 37: Chart on NPH (Neutral Protamine Hagedorn) - Year-over-year growth 2023-2028 (%); Exhibit 38: Data Table on NPH (Neutral Protamine Hagedorn) - Year-over-year growth 2023-2028 (%); 6.5 Market opportunity by Product; Exhibit 39: Market opportunity by Product ($ million); Exhibit 40: Data Table on Market opportunity by Product ($ million)
7 Market Segmentation by Application: 7.1 Market segments; Exhibit 41: Chart on Application - Market share 2023-2028 (%); Exhibit 42: Data Table on Application - Market share 2023-2028 (%); 7.2 Comparison by Application; Exhibit 43: Chart on Comparison by Application; Exhibit 44: Data Table on Comparison by Application; 7.3 Type I diabetes - Market size and forecast 2023-2028; Exhibit 45: Chart on Type I diabetes - Market size and forecast 2023-2028 ($ million); Exhibit 46: Data Table on Type I diabetes - Market size and forecast 2023-2028 ($ million); Exhibit 47: Chart on Type I diabetes - Year-over-year growth 2023-2028 (%); Exhibit 48: Data Table on Type I diabetes - Year-over-year growth 2023-2028 (%); 7.4 Type II diabetes - Market size and forecast 2023-2028; Exhibit 49: Chart on Type II diabetes - Market size and forecast 2023-2028 ($ million); Exhibit 50: Data Table on Type II diabetes - Market size and forecast 2023-2028 ($ million); Exhibit 51: Chart on Type II diabetes - Year-over-year growth 2023-2028 (%); Exhibit 52: Data Table on Type II diabetes - Year-over-year growth 2023-2028 (%); 7.5 Market opportunity by Application; Exhibit 53: Market opportunity by Application ($ million); Exhibit 54: Data Table on Market opportunity by Application ($ million)
8 Market Segmentation by Distribution Channel: 8.1 Market segments; Exhibit 55: Chart on Distribution Channel - Market share 2023-2028 (%); Exhibit 56: Data Table on Distribution Channel - Market share 2023-2028 (%); 8.2 Comparison by Distribution Channel; Exhibit 57: Chart on Comparison by Distribution Channel; Exhibit 58: Data Table on Comparison by Distribution Channel; 8.3 Retail - Market size and forecast 2023-2028; Exhibit 59: Chart on Retail - Market size and forecast 2023-2028 ($ million); Exhibit 60: Data Table on Retail - Market size and forecast 2023-2028 ($ million); Exhibit 61: Chart on Retail - Year-over-year growth 2023-2028 (%); Exhibit 62: Data Table on Retail - Year-over-year growth 2023-2028 (%); 8.4 Hospitals - Market size and forecast 2023-2028; Exhibit 63: Chart on Hospitals - Market size and forecast 2023-2028 ($ million); Exhibit 64: Data Table on Hospitals - Market size and forecast 2023-2028 ($ million); Exhibit 65: Chart on Hospitals - Year-over-year growth 2023-2028 (%); Exhibit 66: Data Table on Hospitals - Year-over-year growth 2023-2028 (%); 8.5 Market opportunity by Distribution Channel; Exhibit 67: Market opportunity by Distribution Channel ($ million); Exhibit 68: Data Table on Market opportunity by Distribution Channel ($ million)
9 Customer Landscape: 9.1 Customer landscape overview; Exhibit 69: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; 10.1 Market drivers; 10.2 Market challenges; 10.3 Impact of drivers and challenges; Exhibit 70: Impact of drivers and challenges in 2023 and 2028; 10.4 Market trends; 11.1 Overview; 11.2 Vendor landscape; Exhibit 71: Overview on Criticality of inputs and Factors of differentiation; 11.3 Landscape disruption; Exhibit 72: Overview on factors of disruption; 11.4 Industry risks; Exhibit 73: Impact of key risks on business; 12.1 Vendors covered; Exhibit 74: Vendors covered; 12.2 Market positioning of vendors; Exhibit 75: Matrix on vendor position and classification; 12.3 Becton Dickinson and Co.; Exhibit 76: Becton Dickinson and Co. - Overview; Exhibit 77: Becton Dickinson and Co. - Business segments; Exhibit 78: Becton Dickinson and Co. - Key news; Exhibit 79: Becton Dickinson and Co. - Key offerings; Exhibit 80: Becton Dickinson and Co. - Segment focus; 12.4 Biocon Ltd.; Exhibit 81: Biocon Ltd. - Overview; Exhibit 82: Biocon Ltd. - Business segments; Exhibit 83: Biocon Ltd. - Key offerings; Exhibit 84: Biocon Ltd. - Segment focus; 12.5 Biomm; Exhibit 85: Biomm - Overview; Exhibit 86: Biomm - Product / Service; Exhibit 87: Biomm - Key offerings; 12.6 Eli Lilly and Co.; Exhibit 88: Eli Lilly and Co. - Overview; Exhibit 89: Eli Lilly and Co. - Product / Service; Exhibit 90: Eli Lilly and Co. - Key news; Exhibit 91: Eli Lilly and Co. - Key offerings; 12.7 Empreendimentos Pague Menos SA; Exhibit 92: Empreendimentos Pague Menos SA - Overview; Exhibit 93: Empreendimentos Pague Menos SA - Product / Service; Exhibit 94: Empreendimentos Pague Menos SA - Key offerings; 12.8 Gulf Pharmaceutical Industries; Exhibit 95: Gulf Pharmaceutical Industries - Overview; Exhibit 96: Gulf Pharmaceutical Industries - Product / Service; Exhibit 97: Gulf Pharmaceutical Industries - Key offerings; 12.9 MannKind Corp.; Exhibit 98: MannKind Corp. - Overview; Exhibit 99: MannKind Corp. - Product / Service; Exhibit 100: MannKind Corp. - Key offerings; 12.10 Medtronic Plc; Exhibit 101: Medtronic Plc - Overview; Exhibit 102: Medtronic Plc - Business segments; Exhibit 103: Medtronic Plc - Key news; Exhibit 104: Medtronic Plc - Key offerings; Exhibit 105: Medtronic Plc - Segment focus; 12.11 Merck and Co. Inc.; Exhibit 106: Merck and Co. Inc. - Overview; Exhibit 107: Merck and Co. Inc. - Business segments; Exhibit 108: Merck and Co. Inc. - Key news; Exhibit 109: Merck and Co. Inc. - Key offerings; Exhibit 110: Merck and Co. Inc. - Segment focus; 12.12 Novartis AG; Exhibit 111: Novartis AG - Overview; Exhibit 112: Novartis AG - Business segments; Exhibit 113: Novartis AG - Key offerings; Exhibit 114: Novartis AG - Segment focus; 12.13 Novo Nordisk AS; Exhibit 115: Novo Nordisk AS - Overview; Exhibit 116: Novo Nordisk AS - Business segments; Exhibit 117: Novo Nordisk AS - Key offerings; Exhibit 118: Novo Nordisk AS - Segment focus; 12.14 Sanofi SA; Exhibit 119: Sanofi SA - Overview; Exhibit 120: Sanofi SA - Business segments; Exhibit 121: Sanofi SA - Key news; Exhibit 122: Sanofi SA - Key offerings; Exhibit 123: Sanofi SA - Segment focus; 12.15 Wockhardt Ltd.; Exhibit 124: Wockhardt Ltd. - Overview; Exhibit 125: Wockhardt Ltd. - Product / Service; Exhibit 126: Wockhardt Ltd. - Key offerings; 13.1 Scope of the report; 13.2 Inclusions and exclusions checklist; Exhibit 127: Inclusions checklist; Exhibit 128: Exclusions checklist; 13.3 Currency conversion rates for US$; Exhibit 129: Currency conversion rates for US$; 13.4 Research methodology; Exhibit 130: Research methodology; Exhibit 131: Validation techniques employed for market sizing; Exhibit 132: Information sources; 13.5 List of abbreviations; Exhibit 133: List of abbreviations
Exhibits:: Exhibits1: Executive Summary - Chart on Market Overview; Exhibits2: Executive Summary - Data Table on Market Overview; Exhibits3: Executive Summary - Chart on Country Market Characteristics; Exhibits4: Executive Summary - Chart on Market Segmentation by Product; Exhibits5: Executive Summary - Chart on Market Segmentation by Application; Exhibits6: Executive Summary - Chart on Market Segmentation by Distribution Channel; Exhibits7: Executive Summary - Chart on Vendor Market Positioning; Exhibits8: Parent market; Exhibits9: Market Characteristics; Exhibits10: Offerings of vendors included in the market definition; Exhibits11: Market segments; Exhibits12: Chart on Brazil - Market size and forecast 2023-2028 ($ million); Exhibits13: Data Table on Brazil - Market size and forecast 2023-2028 ($ million); Exhibits14: Chart on Brazil: Year-over-year growth 2023-2028 (%); Exhibits15: Data Table on Brazil: Year-over-year growth 2023-2028 (%); Exhibits16: Historic Market Size - Data Table on human insulin drugs market in Brazil 2018 - 2022 ($ million); Exhibits17: Historic Market Size - Product Segment 2018 - 2022 ($ million); Exhibits18: Historic Market Size - Application Segment 2018 - 2022 ($ million); Exhibits19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million); Exhibits20: Five forces analysis - Comparison between 2023 and 2028; Exhibits21: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028; Exhibits22: Bargaining power of suppliers - Impact of key factors in 2023 and 2028; Exhibits23: Threat of new entrants - Impact of key factors in 2023 and 2028; Exhibits24: Threat of substitutes - Impact of key factors in 2023 and 2028; Exhibits25: Threat of rivalry - Impact of key factors in 2023 and 2028; Exhibits26: Chart on Market condition - Five forces 2023 and 2028; Exhibits27: Chart on Product - Market share 2023-2028 (%); Exhibits28: Data Table on Product - Market share 2023-2028 (%); Exhibits29: Chart on Comparison by Product; Exhibits30: Data Table on Comparison by Product; Exhibits31: Chart on Basal insulin analog - Market size and forecast 2023-2028 ($ million); Exhibits32: Data Table on Basal insulin analog - Market size and forecast 2023-2028 ($ million); Exhibits33: Chart on Basal insulin analog - Year-over-year growth 2023-2028 (%); Exhibits34: Data Table on Basal insulin analog - Year-over-year growth 2023-2028 (%); Exhibits35: Chart on NPH (Neutral Protamine Hagedorn) - Market size and forecast 2023-2028 ($ million); Exhibits36: Data Table on NPH (Neutral Protamine Hagedorn) - Market size and forecast 2023-2028 ($ million); Exhibits37: Chart on NPH (Neutral Protamine Hagedorn) - Year-over-year growth 2023-2028 (%); Exhibits38: Data Table on NPH (Neutral Protamine Hagedorn) - Year-over-year growth 2023-2028 (%); Exhibits39: Market opportunity by Product ($ million); Exhibits40: Data Table on Market opportunity by Product ($ million); Exhibits41: Chart on Application - Market share 2023-2028 (%); Exhibits42: Data Table on Application - Market share 2023-2028 (%); Exhibits43: Chart on Comparison by Application; Exhibits44: Data Table on Comparison by Application; Exhibits45: Chart on Type I diabetes - Market size and forecast 2023-2028 ($ million); Exhibits46: Data Table on Type I diabetes - Market size and forecast 2023-2028 ($ million); Exhibits47: Chart on Type I diabetes - Year-over-year growth 2023-2028 (%); Exhibits48: Data Table on Type I diabetes - Year-over-year growth 2023-2028 (%); Exhibits49: Chart on Type II diabetes - Market size and forecast 2023-2028 ($ million); Exhibits50: Data Table on Type II diabetes - Market size and forecast 2023-2028 ($ million); Exhibits51: Chart on Type II diabetes - Year-over-year growth 2023-2028 (%); Exhibits52: Data Table on Type II diabetes - Year-over-year growth 2023-2028 (%); Exhibits53: Market opportunity by Application ($ million); Exhibits54: Data Table on Market opportunity by Application ($ million); Exhibits55: Chart on Distribution Channel - Market share 2023-2028 (%); Exhibits56: Data Table on Distribution Channel - Market share 2023-2028 (%); Exhibits57: Chart on Comparison by Distribution Channel; Exhibits58: Data Table on Comparison by Distribution Channel; Exhibits59: Chart on Retail - Market size and forecast 2023-2028 ($ million); Exhibits60: Data Table on Retail - Market size and forecast 2023-2028 ($ million); Exhibits61: Chart on Retail - Year-over-year growth 2023-2028 (%); Exhibits62: Data Table on Retail - Year-over-year growth 2023-2028 (%); Exhibits63: Chart on Hospitals - Market size and forecast 2023-2028 ($ million); Exhibits64: Data Table on Hospitals - Market size and forecast 2023-2028 ($ million); Exhibits65: Chart on Hospitals - Year-over-year growth 2023-2028 (%); Exhibits66: Data Table on Hospitals - Year-over-year growth 2023-2028 (%); Exhibits67: Market opportunity by Distribution Channel ($ million); Exhibits68: Data Table on Market opportunity by Distribution Channel ($ million); Exhibits69: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Exhibits70: Impact of drivers and challenges in 2023 and 2028; Exhibits71: Overview on Criticality of inputs and Factors of differentiation; Exhibits72: Overview on factors of disruption; Exhibits73: Impact of key risks on business; Exhibits74: Vendors covered; Exhibits75: Matrix on vendor position and classification; Exhibits76: Becton Dickinson and Co. - Overview; Exhibits77: Becton Dickinson and Co. - Business segments; Exhibits78: Becton Dickinson and Co. - Key news; Exhibits79: Becton Dickinson and Co. - Key offerings; Exhibits80: Becton Dickinson and Co. - Segment focus; Exhibits81: Biocon Ltd. - Overview; Exhibits82: Biocon Ltd. - Business segments; Exhibits83: Biocon Ltd. - Key offerings; Exhibits84: Biocon Ltd. - Segment focus; Exhibits85: Biomm - Overview; Exhibits86: Biomm - Product / Service; Exhibits87: Biomm - Key offerings; Exhibits88: Eli Lilly and Co. - Overview; Exhibits89: Eli Lilly and Co. - Product / Service; Exhibits90: Eli Lilly and Co. - Key news; Exhibits91: Eli Lilly and Co. - Key offerings; Exhibits92: Empreendimentos Pague Menos SA - Overview; Exhibits93: Empreendimentos Pague Menos SA - Product / Service; Exhibits94: Empreendimentos Pague Menos SA - Key offerings; Exhibits95: Gulf Pharmaceutical Industries - Overview; Exhibits96: Gulf Pharmaceutical Industries - Product / Service; Exhibits97: Gulf Pharmaceutical Industries - Key offerings; Exhibits98: MannKind Corp. - Overview; Exhibits99: MannKind Corp. - Product / Service; Exhibits100: MannKind Corp. - Key offerings; Exhibits101: Medtronic Plc - Overview; Exhibits102: Medtronic Plc - Business segments; Exhibits103: Medtronic Plc - Key news; Exhibits104: Medtronic Plc - Key offerings; Exhibits105: Medtronic Plc - Segment focus; Exhibits106: Merck and Co. Inc. - Overview; Exhibits107: Merck and Co. Inc. - Business segments; Exhibits108: Merck and Co. Inc. - Key news; Exhibits109: Merck and Co. Inc. - Key offerings; Exhibits110: Merck and Co. Inc. - Segment focus; Exhibits111: Novartis AG - Overview; Exhibits112: Novartis AG - Business segments; Exhibits113: Novartis AG - Key offerings; Exhibits114: Novartis AG - Segment focus; Exhibits115: Novo Nordisk AS - Overview; Exhibits116: Novo Nordisk AS - Business segments; Exhibits117: Novo Nordisk AS - Key offerings; Exhibits118: Novo Nordisk AS - Segment focus; Exhibits119: Sanofi SA - Overview; Exhibits120: Sanofi SA - Business segments; Exhibits121: Sanofi SA - Key news; Exhibits122: Sanofi SA - Key offerings; Exhibits123: Sanofi SA - Segment focus; Exhibits124: Wockhardt Ltd. - Overview; Exhibits125: Wockhardt Ltd. - Product / Service; Exhibits126: Wockhardt Ltd. - Key offerings; Exhibits127: Inclusions checklist; Exhibits128: Exclusions checklist; Exhibits129: Currency conversion rates for US$; Exhibits130: Research methodology; Exhibits131: Validation techniques employed for market sizing; Exhibits132: Information sources; Exhibits133: List of abbreviations